公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | The Demonstration of High-Quality Carbon Nanotubes as Through-Silicon Vias (TSVs) for Three-Dimensional Connection Stacking and Power-Via Technology | Yen C; Chang S; Chen K; Feng Y; Chen L; Liao B; Lee M; Chen S; Liao M.; MING-HAN LIAO | IEEE Transactions on Electron Devices | |||
2015 | Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy | Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU ; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. | Clinical Cancer Research | 408 | 382 | |
2013 | Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial | Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU ; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T. | The Lancet Oncology | 277 | 247 | |
2009 | Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer | Mok T.S.K.; Wu Y.-L.; CHONG-JEN YU ; Zhou C.; Chen Y.-M.; Zhang L.; Ignacio J.; Liao M.; Srimuninnimit V.; Boyer M.J.; Chua-Tan M.; Sriuranpong V.; Sudoyo A.W.; Jin K.; Johnston M.; Chui W.; Lee J.-S. | Journal of Clinical Oncology | 207 | 178 |